KFB Integrates Genomatix GeneChip® Analysis Pipeline into its Product Portfolio.
News Feb 20, 2006
KFB - Center of Excellence for Fluorescent Bioanalysis, an authorized Affymetrix Service Provider, and Genomatix Software GmbH have signed a cooperation and license agreement that integrates the Genomatix GeneChip® Analysis-Pipeline with KFB's Affymetrix GeneChip® Services.
These combined services will be made available to the KFB customer base in industry and academic institutions.
Customers will receive results for their microarray experiments which are extensively analyzed based on KFB's and Genomatix' expertise.
In addition, they will have temporary access to the full functionality of BiblioSphere PathwayEdition, one of the largest data base and analysis systems for biological networks.
The crucial difference to current GeneChip® analysis methods is the low level processing of the raw data with ChipInspector.
ChipInspector, basing analysis on the latest up-to-date genome annotation, treats each oligo-nucleotide probe per se without the statistical averaging as established with most other methods
Dr. Martin Seifert, Genomatix' VP of Microarray Business and Collaborative Research says, "Our proprietary single probe approach in ChipInspector is a result of years of hard work on the ElDorado genome annotation pipeline. Now, we can attribute the single DNA probes to a specific and unique transcript."
"This results in an unsurpassed increase in signal to noise distance, crucial for the monitoring of low level gene expression changes, or when analyzing samples with limited RNA such as from micro-dissected paraffin embedded samples."
"ChipInspector was publicly released only a few months ago, but there are a series of peer reviewed scientific publications detailing outstanding results generated with these new tools currently underway."
The logical next step for microarray data analysis is to look at the significant changes in gene expression, bring them into a biological context, and classify and rank the experimental findings into biological processes.
This is achieved by BiblioSphere PathwayEdition which not only analyses the entire underlying networks, but also accounts for organisation of DNA promoter sequences linked to the gene regulation seen.
"A KFB-customer receives a thoroughly compiled report of the findings. But beyond this static report, live dynamic results are delivered allowing for the customer to do further scientific analyses and research with the temporary full access to BiblioSphere PathwayEdition," says Klaus May, Director of Marketing & Sales at Genomatix. "This is an innovative concept which was very well received at pilot studies!"
As genome editing technologies advance toward clinical therapies, they are raising hopes of a completely new way to treat disease. However, challenges need to be addressed before potential treatments can be widely used in patients. To tackle these challenges, the National Institutes of Health has launched the Somatic Cell Genome Editing program, which has awarded multiple grants including more than $3.6 million to assess the safety of genome editing in human cells and tissues.